2Garcia RL, Coltrera MD, Gown AM. Analysis of proliferative grade using anti-PCNA/eyelin monoelonal antibodies in fixed, embedded tissues. Comparison with flow eytometrie analysis. Am J Pathol, 1989,134:733-739.
3Nam NH, Parang K. Current targets for anticaneer drug discovery. Curr Drug Targets, 2003,4 : 159-179.
4Arnbrosini G, Adida C, Altieri DC. A novel anti-apoptosis gene, survivin, expressed in cancer and lyrnphoma. Nat Med, 1997,3:917-921.
5Li F. Survivin study: what is the next wave? J Cell Physiol, 2003,197:8-29.
6Nakamura M, Tsuji N, Asanuma K, et al. Survivin as a predictor of cis-diamminedichloroplatinum sensitivity in gastric cancer patients. Cancer Sci, 2004,95 :44-51.
7Ross JS, McKenna BJ. The HER-2/neu oncogene in tumors of the gastrointestinal tract. Cancer Invest, 2001, 19: 554 -568.
8Siddiqa A, Long LM, Li L, et al. Expression of HER-2 in MCF-7 breast cancer cells modulates anti-apoptotic proteins Survivin and Bcl-2 via the extracellular signal-related kinase (ERK) and phosphoinositide-3 kinase (PI3K) signalling pathways. BMC Cancer, 2008,8:129.
9Polkowski W, van Sandick JW, Offerhaus GJ, et al. Prognostic value of Lauren classification and c-erbB-2 oncogene overexpression in adenocarcinoma of the esophagus and gastroesophageal junction. Ann Surg Oncol, 1999, 6:290-297.
10Juvan R, Hudler P, Gazvoda B,et al. Significance of genetic abnormalities of p53 protein in Slovenian patients with gastric carcinoma. Croat Med J, 2007,48 : 207-217.
